Authors

• Lorenzo Antonuzzo (ORCID: https://orcid.org/0000-0003-3349-5604)
• Julie Wang (ORCID: https://orcid.org/0000-0001-5956-0123)
• Magdalena Żotkiewicz
• Roopinder Gillmore (ORCID: https://orcid.org/0000-0001-8620-3885)
• Marielle Holmblad
• Gina M. Vaccaro (ORCID: https://orcid.org/0000-0003-3934-0806)
• Mila Petrova
• Joon Oh Park (ORCID: https://orcid.org/0000-0001-6502-2612)
• Aumkhae Sookprasert (ORCID: https://orcid.org/0000-0003-0362-1235)
• Do‐Youn Oh (ORCID: https://orcid.org/0000-0003-1663-9901)
• Sheng‐Shun Yang
• Hidenori Takahashi (ORCID: https://orcid.org/0000-0003-4801-3540)
• Nana Rokutanda
• Juan Cundom

Institutions

• Khon Kaen University (TH)
• The Royal Free Hospital (GB)
• Providence Portland Medical Center (US)
• Samsung Medical Center (KR)
• New Generation University College (ET)
• Seoul National University Hospital (KR)
• Medical University of Sofia (BG)
• Taichung Veterans General Hospital (TW)
• AstraZeneca (France) (FR)
• Instituto de Diagnóstico e Investigaciones Metabólicas (AR)
• AstraZeneca (Netherlands) (NL)
• Azienda Ospedaliero-Universitaria Careggi (IT)
• National University College (PR)
• AstraZeneca (Spain) (ES)
• AstraZeneca (United States) (US)
• Osaka International Cancer Institute (JP)
• University of Florence (IT)
• University College London (GB)
• Sungkyunkwan University (KR)

Publication Details

Journal

The Oncologist

Published

2025-07-01

DOI

https://doi.org/10.1093/oncolo/oyaf148

Citations

1

Primary Topic

Cholangiocarcinoma and Gallbladder Cancer Studies

Type

article

Field-Weighted Citation Impact

2.01

Funders

• AstraZeneca